24 Pharma Trends Report, sponsored by Arvato Systems, dissects emerging trends. From the impact of generative AI on the supply chain to mature quality management plans for biomanufacturers, excipient market growth, biologics outsourcing, and more, these expert insights .
Pharma market overview – US & Europe 1 Uncover the transformative trends that will drive the life sciences industry ahead, backed by expert commentary and data-driven insights. LIFE SCIENCES ...
This report examines research and development (R&D) by the pharmaceutical industry. Spending on R&D and Its Results. Spending on R&D and the introduction of new drugs have both increased in the past two decades. • In 2019, the pharmaceutical industry spent $83 billion dollars on R&D. Adjusted for inflation,
industry has some way to go to become a trusted part of the healthcare ecosystem. Although value-based pricing (VBP) comes with its fair share of risks and challenges, as evidenced by Novartis’ Entresto drug, there is large potential to create a win-win situation for multiple healthcare stakeholders if structured and implemented correctly.6
2024年2月6日 · • The federal government is beginning to take on the greed of the pharmaceutical industry. Medicare, for the first time, can negotiate the price of drugs like Eliquis and Stelara. Manufacturers are also now required to pay rebates to Medicare for increasing prices faster than the rate of inflation.
Several premium-priced innovative drugs are expected to be launched in EU4 and UK in the forecast period, driving market value growth. Among EU4+UK, the highest growth contributor is Germany, accounting for 4.5% of aggregate increase in sales.
THE PHARMACEUTICAL INDUSTRY: A KEY ASSET TO THE EUROPEAN ECONOMY As well as driving medical progress by researching, developing and bringing new medicines that improve health and quality of life for patients around the world, the research-based pharmaceutical industry is a key asset of the European economy. It is one of
Indian pharma industry can embark on a vision of establishing India’s global leadership in life sciences, while driving deeper domestic access and affordability. Industry can work towards four primary goals as part of this vision for 2030.
Thanks to advances in science and technology, the research-based pharmaceutical industry is entering an exciting new era in medicines development. Research methods are evolving and we have many promising prospects on the horizon, with ground-breaking cell and gene therapies being increasingly available*.
As global logistics ground to a halt, pharma companies had to reallocate resources and reassess how to deploy their human capital, processes, priorities and supply chains in order to provide the...
The Global pharmaceutical industry is estimated to have grown to USD~1,250bln in CY21 (CY20: USD~1,228bln), posting a growth of ~1.8% YoY; the overall industry size is expected to reach to USD~1,700bln by CY25 with a CAGR of ~8%.
Factors such as the COVID-19 pandemic, inflation, geopolitics, new therapeutic modalities, and new ways of working make it vital for pharmacos to carefully reconsider their long-term choices in sourcing, manufacturing, and supply chain.
pharmaceutical industry evolves towards cutting-edge therapeutics and innovative delivery systems, the demand for sophisticated APIs is likely to increase.1 Global molecule market: A surge in value and growth over the years (2014–MAT 2023) The molecule market has shown consistent growth, with key players implementing strategies to maintain this
research-based pharmaceutical industry is entering an exciting new era in medicines development. Research methods are evolving and we have many promising prospects on the horizon – from the possibilities offered by personalised medicines, to the potential offered by harnessing the power of big data. The innovative pharmaceutical industry
In this white paper, we take an in-depth look at market access in the United States, one of the most sought-after subsegments of pharma commercialization.
The pharmaceutical industry is characterized by atypical economics and an unusual intersection of regulation, patent and antitrust law. The supply side of the industry includes originator and generic prescription and over-the-counter (OTC) drugs, in addition to wholesalers and retail pharmacy services.
Analysis from six leading US experts – following extensive interviews and data collection – provides an essential guide to near-term priorities, medium-term capacity constraints and longer-term shifts underway in the US pharma market supply chain.
Based on the data generated from the database, we selected the top 5 therapeutic areas by the number of drugs for each company to illustrate. Moreover, the clinical landscapes of products were...
derstanding the pharmaceutical value chain. This includes the full set of activities that occurs between the point when a medicine is manufac-tured and shipped from a production or impo.
The products manufactured by the Indian pharmaceutical industry can be broadly classified into bulk drugs (active pharmaceutical ingredients - API) and formulations. Of the total number of pharmaceutical manufacturers, about 77% produce formulations, while the remaining 23% manufacture bulk drugs6.